Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance

被引:0
作者
Evangelos Oikonomou
Konstantinos Mourouzis
Petros Fountoulakis
Georgios Angelos Papamikroulis
Gerasimos Siasos
Alexis Antonopoulos
Georgia Vogiatzi
Sotiris Tsalamadris
Manolis Vavuranakis
Dimitris Tousoulis
机构
[1] National and Kapodistrian University of Athens Medical School,1st Department of Cardiology, ‘Hippokration’ Hospital
来源
Heart Failure Reviews | 2018年 / 23卷
关键词
Heart failure; Diabetes mellitus; Systolic dysfunction; Diastolic dysfunction; Peroxisome proliferator-activated receptors; Thiazolidinediones;
D O I
暂无
中图分类号
学科分类号
摘要
Heart failure (HF) is a common cardiac syndrome, whose pathophysiology involves complex mechanisms, some of which remain unknown. Diabetes mellitus (DM) constitutes not only a glucose metabolic disorder accompanied by insulin resistance but also a risk factor for cardiovascular disease and HF. During the last years though emerging data set up, a bidirectional interrelationship between these two entities. In the case of DM impaired calcium homeostasis, free fatty acid metabolism, redox state, and advance glycation end products may accelerate cardiac dysfunction. On the other hand, when HF exists, hypoperfusion of the liver and pancreas, b-blocker and diuretic treatment, and autonomic nervous system dysfunction may cause impairment of glucose metabolism. These molecular pathways may be used as therapeutic targets for novel antidiabetic agents. Peroxisome proliferator-activated receptors (PPARs) not only improve insulin resistance and glucose and lipid metabolism but also manifest a diversity of actions directly or indirectly associated with systolic or diastolic performance of left ventricle and symptoms of HF. Interestingly, they may beneficially affect remodeling of the left ventricle, fibrosis, and diastolic performance but they may cause impaired water handing, sodium retention, and decompensation of HF which should be taken into consideration in the management of patients with DM. In this review article, we present the pathophysiological data linking HF with DM and we focus on the molecular mechanisms of PPARs agonists in left ventricle systolic and diastolic performance providing useful insights in the molecular mechanism of this class of metabolically active regiments.
引用
收藏
页码:389 / 408
页数:19
相关论文
共 50 条
  • [42] Today's challenges and tomorrow's opportunities: Ligands to peroxisome proliferator-activated receptors as therapies for type 2 diabetes and the metabolic syndrome
    Miller, Anne Reifel
    DRUG DEVELOPMENT RESEARCH, 2006, 67 (07) : 574 - 578
  • [43] Serum Peroxisome Proliferator-activated Receptor Gamma Coactivator-1α Related to Myocardial Energy Expenditure in Patients With Chronic Heart Failure
    Chen, Pingan
    Zhan, Qiong
    Bai, Yujia
    Huang, Xingfu
    Wang, Peng
    Pan, Yizhi
    Li, Shaonan
    Fu, Shenshen
    Lai, Wenyan
    Zeng, Qingchun
    Ren, Hao
    Xu, Dingli
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 357 (03) : 205 - 212
  • [44] Impact of Diabetes Mellitus on the Prognosis of Patients With Heart Failure and Preserved Left Ventricle Ejection Fraction: Insights From the TOPCAT Study
    Huynh, Thao
    Harty, Brian
    Assmann, Susan
    O'Meara, Eileen
    Anand, Inder
    Fleg, Jerome
    Claggett, Brian
    Pitt, Bertram
    Rouleau, Jean
    CIRCULATION, 2015, 132
  • [45] Peroxisome proliferator-activated receptor Pro12Ala polymorphism and the risks of gestational diabetes mellitus An updated meta-analysis of 12 studies
    Wang, Lihong
    Xu, Wenting
    Wang, Xu
    MEDICINE, 2016, 95 (44)
  • [46] The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats
    Linz, Wolfgang
    Wohlfart, Paulus
    Baader, Manuel
    Breitschopf, Kristin
    Falk, Eugen
    Schaefer, Hans-Ludwig
    Gerl, Martin
    Kramer, Werner
    Ruetten, Hartmut
    ACTA PHARMACOLOGICA SINICA, 2009, 30 (07) : 935 - 946
  • [47] Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure
    Shimano, Masayuki
    Tsuji, Yukiomi
    Inden, Yasuya
    Kitamura, Kazuhisa
    Uchikawa, Tomohiro
    Harata, Shuji
    Nattel, Stanley
    Murohara, Toyoaki
    HEART RHYTHM, 2008, 5 (03) : 451 - 459
  • [48] The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats
    Wolfgang Linz
    Paulus Wohlfart
    Manuel Baader
    Kristin Breitschopf
    Eugen Falk
    Hans-Ludwig Schäfer
    Martin Gerl
    Werner Kramer
    Hartmut Rütten
    Acta Pharmacologica Sinica, 2009, 30 : 935 - 946
  • [49] Peroxisome proliferator-activated receptor (PPAR)-alpha plays a more critical role than PPAR-gamma in mitochondrial protection in rats with heart failure following myocardial infarction
    Yang, Yongyao
    Zhang, Hongming
    Li, Xiaoyan
    Wu, Qiang
    EXPERIMENTAL & CLINICAL CARDIOLOGY, 2013, 19 (01)
  • [50] Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism
    Kamimura, Daisuke
    Uchino, Kazuaki
    Ishigami, Tomoaki
    Hall, Michael E.
    Umemura, Satoshi
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2016, 68 (02) : 155 - 161